Nanoscale size controllable and surface modifiable zeolitic imidazolate framework-8−poly(acrylic acid sodium salt) (ZIF-8−PAAS) nanocomposites are fabricated by employing PAAS nanospheres as a soft template. These ZIF-8−PAAS nanocomposites have different sizes ranging from 30 to 200 nm and exhibit different crystallinity, and pH sensitivity. These nanocomposites can be employed as vectors to deliver doxorubicin for anticancer therapy, leading to greatly enhanced drug therapeutic efficacy when tested in cell lines and mice model. Systematic toxicity investigation including hematoxylin and eosin staining analysis of tumor and major organs, hematology analysis, and blood chemistry analysis indicates that the nanocomposites possess high biocompatibility. This work provides a strategy to make metal−organic frameworks (MOFs) nanocomposites with size tunability in nanoscale and flexible surface modification for various applications.
INTRODUCTION
Crystalline metal−organic frameworks (MOFs) are fabricated by reticular synthesis, in which strong bonds are formed between metal ions (inorganic) and organic linker molecules. 1, 2 As an emerging crystalline material, MOFs exhibit up to 90% free volume porosity and possess a surface area of over 6000 m 2 /g. 3 With extraordinary flexibility of selection of organic and inorganic components (more than 20,000 kinds), MOFs can be rationally tuned with versatile structure, surface area, pore size, and property. 4−7 Because of these superior characteristics, MOFs have been widely used for air purification, 8−10 gas separations/storage, 11−14 chemical sensors, 15, 16 heterogeneous catalysis, 17−20 and biomedical engineering. 21−28 For many applications, it is of great importance to rationally design MOFs with optimal surface chemistry and size tunability. Taking drug delivery as an example, MOFs were first used as a drug carrier in 2006. 29, 30 Since then, MOFs have been developed to a nanoregime of below 200 nm for improved drug delivery and bioimaging because materials within this size range can have high cellular uptake and long blood-circulation time 31, 32 and these make them good candidates as drug carriers. 33−38 Despite the progress in recent years of using nanoscale MOFs (NMOFs) for drug delivery, negligible work has been reported to produce size controllable NMOFs. Very recently, Park et al. reported production of size controllable (30−190 nm) Zr(IV)-based porphyrinic MOFs by adjusting the concentration of reactant benzoic acid. The results demonstrated that the MOFs with a size of 90 nm have significantly higher cellular uptake and in vivo photodynamic therapy efficacy when used to deliver a photosensitizer than those of other sizes. 39 However, the specific parameters controlling the size of MOFs need to be tuned for each type of material. Beyond size controllability, the surfaces of nanomaterials play an important role in biological and medical applications. Currently, stabilization of MOFs in aqueous solution is predominantly reliant on surface coating, but the conventional polymer or silica coating may block the pores on the surface of MOFs, leading to a decrease of porosity and correspondingly drug loading capacity. 40 To address these bottlenecks of making size controllable and surface tunable NMOFs for efficient drug delivery, herein, we propose a method of employing poly(acrylic acid sodium salt) (PAAS) nanospheres as a soft template to produce size controllable and surface modifiable zeolitic imidazolate framework-8−poly(acrylic acid sodium salt) (ZIF-8−PAAS) nanocomposites. In this unique approach, we hypothesize that the particle size can be precisely controlled by the molecular weight of the PAAS soft template; and instead of directly modifying MOFs for stabilization, the surface modification may be constructed on the PAAS template. To confirm our hypothesis, we systematically studied the approach of using PAAS as templates for synthesizing NMOFs with controllable sizes of below 200 nm and establishing desirable surface modification on PAAS. Through extensive studies, we found that surface modification molecules should be conjugated to PAAS first and then the conjugated polymer be used as a template for MOFs growth. In this way, NMOFs with high stability and cancer cell targeting ability can be conveniently synthesized. Because surface modification was performed to the PAAS template, it is expected that the high porosity of NMOFs and corresponding drug loading capacity can be retained without being negatively affected by surface modification. To the best of our knowledge, such an approach of using PAAS of different molecular weights to produce NMOFs with size controllability and desirable surface modification has not been reported. After successful preparation of NMOFs, the size, morphology, structure, drug loading, and release under different conditions, in vitro cancer cell killing efficiency, and in vivo tumor inhibition rate and biosafety profiles were investigated in detail. The experimental results demonstrate that these NMOFs possess superior characteristics of high drug loading capacity, pH responsive drug release, excellent tumor inhibition efficacy, and great biocompatibility. Overall, this soft-template method provides a powerful approach to fabricate size and surface controllable NMOFs for high-performance applications.
EXPERIMENTAL SECTION
2.1. Materials and Characterization. PAAS (M w = 20K), isopropyl alcohol, and methanol were purchased from International Laboratory (USA). Zn(NO 3 ) 2 and 2-methylimidazole were ordered from Acros (USA). PAAS (M w = 8K), PAAS (M w = 1.2K), and poly(ethylene glycol) (PEG)−amine (M w = 5000) were bought from Sigma-Aldrich (USA). Doxorubicin (DOX) was from Beijing Zhongshuo Pharmaceutical Technology Development Co., Ltd. (China). Dulbecco's modified Eagle medium (DMEM), fetal bovine serum (FBS), phosphate-buffered saline (PBS), MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), penicillin/ streptomycin, and Hoechst 33342 were obtained from Life Technologies (USA). Cell culture 96-well plates and dishes were obtained from Corning (USA). ζ potential and size distribution were measured by Zetasizer (Malvern). Transmission electron microscopy (TEM) and high-resolution transmission electron microscopy (HRTEM) images were taken on Technai 12 (Philips) and JEOL JEM 2100F, respectively. Scanning electron microscopy (SEM) images were taken on an FEG SEM-XL30. Powder X-ray diffraction (XRD) patterns were collected with D2 Phaser X-ray diffraction using Cu Kα radiation.
2.2. PAAS Nanosphere Fabrication. PAAS (M w = 1.2K, 8K, and 20K) solutions were first diluted to 0.2 g/mL, and then 200 μL of the diluted PAAS solutions (M w 1.2K, 8K, and 20K) were added separately into 4 mL of Milli-Q water (18.2 mΩ) with 5 min stirring. Subsequently, 20, 40, and 80 mL aliquots of isopropyl alcohol were added into PAAS solutions with molecular weights of 1.2K, 8K, and 20K, respectively, with magnetic stirring for making different sizes of PAAS templates.
2.3. ZIF-8-PAAS Nanocomposites Fabrication. The asprepared PAAS nanospheres were mixed with 6.7 mL of 0.1 M Zn(NO 3 ) 2 in methanol solution under stirring for 5 min. Then, the mixture was centrifuged at 2000, 4000, and 6000 rpm for PAAS with M w = 1.2K, 8K, and 20K, respectively. Next, the precipitated PAA-Zn nanospheres were re-dispersed in 20 mL of methanol, followed by addition of 20 mL of 20 mg/mL 2-methylimidazole in methanol under stirring. Finally, the solution was subjected to reaction at 70°C for 12 h.
2.4. PEG Modified ZIF-8 NMOFs Nanocomposites Fabrication. First, 300 μL of 0.2 g/mL PAAS (M w = 8K) solution and 1.5 mL of 2 mg/mL PEG−amine were sequentially added into 1.5 mL of Milli-Q water (18.2 mΩ), followed by overnight stirring in the presence of EDC as a catalyst. Second, 3 mL of Milli-Q water and 24 mL of isopropyl alcohol were added into the solution with magnetic stirring. Third, 8 mL of 0.1 M Zn(NO 3 ) 2 in methanol solution was added and stirred for 5 min. Fourth, the mixture was centrifuged at 10000 rpm for 30 min. Fifth, the precipitation was re-dispersed in 4 mL of methanol, followed by addition of 16 mL of 20 mg/mL 2methylimidazole in methanol under active stirring. Finally, the solution was subjected to reaction at 70°C for 12 h.
2.5. Drug Loading Capacity and Loading Efficiency. Solutions of 400, 200, 100, 50, and 25 μL of 2 mg/mL ZIF-8 NMOFs nanocomposites were added into 200 μL of 2 mg/mL DOX solution, and the mixtures were under stirring for 24 h. The amount of drug loading was determined from the absorbance differences (at 480 nm) of DOX in the solution before and after mixing with ZIF-8 NMOFs nanocomposites. Loading capacity and loading efficiency were calculated by the following equations: (1) loading capacity = [(W t − W f )/W n ] × 100% and (2) loading efficiency = [(W t − W f )/W t ] × 100%, where W t is the total DOX in solution, W f the free DOX after loading, and W n the weight of ZIF-8 NMOFs nanocomposites.
2.6. In Vitro DOX Release Profile. DOX loaded ZIF-8 NMOFs nanocomposites were added into 2 mL of buffer solution (pH = 7.4 and pH = 5) placed on a shaking water bath at 37°C. After different time intervals, 120 μL of the buffer solution was collected and the amount of DOX release was measured by absorbance at 480 nm.
2.7. Fluorescence Microscopy. HeLa cell suspension was seeded onto a sterile glass coverslip in a 35 mm tissue culture dish for 24 h. Then the cell culture medium was replaced with a fresh medium containing DOX loaded ZIF-8 NMOFs nanocomposites (10 wt % DOX) at DOX concentration of 4 μg/mL. At 4 h after incubation, the nuclei were stained by Hoechst 33342 and the coverslip was mounted onto a glass slide for fluorescence microscopy.
2.8. Cell Viability Measurement. HeLa cells were washed twice with PBS. HeLa cells suspended in DMEM (with 10% FBS and 1% penicillin/streptomycin) were plated into 96-well plates (100 μL of DMEM and 1,500−3,000 cells per well). The cells were incubated at 37°C for 24 h before further treatment. Then, another 100 μL of DMEM containing various concentrations of DOX, ZIF-8 NMOFs nanocomposites, and DOX loaded ZIF-8 NMOFs nanocomposites were added into 96-well plates for additional 48 and 72 h incubation. After incubation, the original medium in each well was removed. Subsequently, 180 μL of DMEM (without FBS) and 20 μL of MTT stock solution (5 mg/mL in PBS) were added and incubated for 4 h. Then the medium containing MTT was completely removed, followed by adding 200 μL of dimethyl sulfoxide (DMSO) to each well. Cell viabilities were determined by reading the absorbance of the plates at 540 nm using a BioTek Powerwave XS microplate reader.
2.9. In Vivo Cancer Therapy. The tumor model was developed by injection of 4T1 cells to Balb/C mice (2.5 × 10 6 4T1 cells in 100 μL of PBS). At 7 days after inoculation of the cancer cells, the mice were randomly divided into four groups (n = 4; defined as treatment day 1). Then 200 μL of different drug formulations at a dose of 2.5 mg/mL DOX (referred to as MOF-DOX PEG, MOF-DOX, and DOX) and PBS solution were injected into the different groups of mice via the tail vein on treatment days 1, 7, 13, and 19. The tumor size and body 
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ZIF-8 NMOFs Nanocomposites Preparation and
Characterization. In our study, PAAS nanospheres were synthesized by a deionized water−isopropyl alcohol approach. 41 PAAS with three different molecular weights (M w ) of 1.2K, 8K, and 20K were chosen in the preparation. We found that PAAS nanospheres of different sizes of 105, 79, and 33 nm were formed by self-assembly from PAAS with M w = 1.2K, 8K, and 20K, respectively. The sizes of the nanospheres were measured by dynamic light scattering (DLS; Supporting Information Figure S1 ). SEM also confirms that PAAS nanospheres sizes are around 80 and 35 nm for PAAS with M w of 8K and 20K, respectively (Supporting Information Figure S2 and Figure S3 ). Because Zn 2+ has higher affinity toward -COO − groups in PAAS polymer chains than Na + , PAAS nanospheres were mixed with Zn(NO 3 ) 2 at room temperature for 5 min so that Zn 2+ could replace Na + (Scheme 1). The as-prepared PAA−Zn nanospheres were then reacted Figure S6 ). Fourier transform infrared spectroscopy (FTIR) results show the carbonyl stretching vibration of -COO − at 1580 cm −1 and the stretching vibration of -COOH at 1717 cm −1 , which confirms the existence of -COO − groups in the nanocomposites (Supporting Information Figure S7 ).
To determine the crystal structure of ZIF-8 NMOFs nanocomposites, XRD was performed (Supporting Information Figure S8 ). From the XRD pattern, one can observe that the diffraction patterns of ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) nanocomposites have matched characteristic peaks, suggesting the formation of ZIF-8 crystals. The peaks of the XRD pattern of ZIF-8 (20K) are much sharper and stronger in intensity than those of ZIF-8 (1.2K) and ZIF-8 (8K). This indicates that ZIF-8 (20K) NMOFs nanocomposites possess higher crystallinity than ZIF-8 (8K) and ZIF-8 (1.2K) ones. To further investigate the difference in crystallinity, HRTEM was carried out (Figure 1d−f and Supporting Information Figure  S9 ). From the results, we can find that ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) nanocomposites contain a crystalline region and an amorphous area. Instead, ZIF-8 nanocrystals of a few nanometers are well-dispersed within the PAAS matrix. It is worth noting that, from the HRTEM images, ZIF-8 (20K) NMOFs nanocomposites possess a more well-aligned and larger crystalline region than the ZIF-8 (8K) and ZIF-8 (1.2K) ones, which is in correspondence with the XRD results. Therefore, we can conclude that our method is able to control the crystallinity of fabricated ZIF-8 NMOFs nanocomposites. The energy-dispersive X-ray spectroscopy (EDX) mapping images of ZIF-8 (1.2K) and ZIF-8 (8K) NMOFs nanocomposites demonstrate the Zn element is well-distributed across the nanoparticles, confirming the relatively homogeneous composition (Supporting Information Figure S10 and Figure S11 ).
3.2. In Vitro Study of ZIF-8 NMOFs Nanocomposites. After successful preparation of ZIF-8 NMOFs nanocomposites with different sizes, their drug loading and release capabilities were evaluated. DOX, a well-known anticancer drug, was used as a test case. DOX loading was achieved by simply mixing ZIF-8 NMOFs nanocomposites with DOX in an aqueous solution. Because the pore size of ZIF-8 is very small, DOX is physically adsorbed on the surface of the ZIF-8 nanocomposites. We found that the drug loading capability of the three prepared ZIF-8 NMOFs nanocomposites was different. ZIF-8 (1.2K) NMOFs nanocomposites show much better DOX loading capacity than ZIF-8 (8K) and ZIF-8 (20K) ones (Figure 2a,b) . When the mixing ratio of ZIF-8 NMOFs nanocomposites to DOX is 1:1, the loading efficiencies (weight of loaded DOX/ weight of total DOX) are >97% for ZIF-8 (1.2K) and ZIF-8 (8K) and >87% for ZIF-8 (20K). When the amount of DOX continually increases in the mixture (ZIF-8 to DOX ratios drop to 1:2, 1:4, and 1:8), the loading efficiency drops as the percentage of ZIF-8 NMOFs nanocomposites in the mixture becomes smaller. However, the loading capacity (weight of loaded DOX/weight of ZIF-8) keeps increasing. For example, when the ratio of ZIF-8 NMOFs nanocomposites to DOX is 1:8, every milligram of ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) can load 3.85 (385%), 3.14 (314%), and 1.73 (173%) mg of DOX, with loading efficiencies of 48%, 39%, and 22%, respectively. These values indicate that our fabricated ZIF-8 NMOFs nanocomposites show very high drug loading capacity. The differences of drug loading capacity may be caused by the different crystallinities of the different ZIF-8 NMOFs nanocomposites.
Once confirming that our fabricated ZIF-8 NMOFs nanocomposites display excellent drug loading capacity, we next investigated their release kinetics. ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) NMOFs nanocomposites with drug loading capacity of 100 wt % (the weight of drug and ZIF-8 is equivalent) and 10 wt % (weight of drug/weight of ZIF-8 = 1:10) were selected for in vitro release study (Figure 2c,d) . Under pH 7.4, all ZIF NMOFs nanocomposites can hold DOX molecule relatively firmly for at least 24 h, with only <15% (drug loading, 100 wt %) and <30% (drug loading, 10 wt %) of the loaded drugs released to the buffer solutions. However, when pH drops to 5 (the pH value of tumor tissue or lysosome), drug release becomes faster. Interestingly, these asfabricated ZIF-8 NMOFs nanocomposites display different pH sensitivities. ZIF-8 (1.2K) is found to be more pH sensitive than ZIF-8 (8K) and ZIF-8 (20K). For example, ZIF-8 (1.2K) NMOFs nanocomposites with drug loading capacity of 100 wt % releases greater than 60% of DOX at pH 5, which is much higher than the other two nanocomposites. The possible explanation of the different pH sensitivity is due to the different crystallinity: ZIF (1.2K) NMOFs nanocomposites have less crystallinity than ZIF-8 (8K) and ZIF-8 (20K), resulting in lower stability in acid environments, and thus release of more DOX drug. This explanation was supported by TEM images of ZIF-8 NMOFs nanocomposites after treatment in pH 7.4 and pH 5 buffer solutions. The structures of the vast majority of ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) NMOFs nanocomposites collapse at pH 5, while their structures are relatively stable at pH 7.4, particularly for ZIF-8 (8K) and ZIF-8 (20K); at pH 5, some ZIF-8 (20K) NMOFs nanocomposites can still maintain the structure (Supporting Information Figure  S12 ). Consistent with these findings observed from TEM, DLS shows the mean count rates of ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) NMOFs nanocomposites significantly drop to less than 20 kcps (almost background level) after pH 5 buffer treatment for 2 min. This means that the release of the drug from the MOFs is more efficient at a lower pH value. Overall, ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) NMOFs nanocomposites display different sizes, crystallinities, drug loading capacities, and pH sensitivities ( Table 1) .
Following the study of the release kinetics, the intracellular delivery of different sizes of ZIF-8 NMOFs nanocomposites loaded with DOX was studied, because the size of nanomaterials can dramatically affect their intracellular delivery efficiency. In this study, we selected ZIF-8 NMOFs nanocomposites with DOX loading of 10 wt % to investigate the intracellular delivery efficiencies of the three different ZIF-8 NMOFs nanocomposites. The results are shown in Figure 3 . It is apparent that the intracellular delivery efficiency is size dependent: ZIF-8 (1.2K) < ZIF-8 (8K) < ZIF-8 (20K). After 4 h incubation, the HeLa cells treated with ZIF-8 (20K) (46 nm) NMOFs nanocomposites show a much stronger fluorescence signal from DOX than those treated with ZIF-8 (1.2K) (190 nm) and ZIF-8 (8K) (98 nm) NMOFs nanocomposites.
Subsequently, we characterized the HeLa cell viability after incubation with ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) NMOFs nanocomposites for 48 and 72 h (Figure 4 ). Again, we chose ZIF-8 NMOFs nanocomposites with 10 wt % DOX loading for testing. The results show that significantly improved delivery efficiency can be achieved with the aid of ZIF-8 NMOFs nanocomposites, particularly with the nanocomposites made from PAAS of molecular weight of 20K Da (Figure 4 ). This is well-matched with our data showing that ZIF-8 (20K) enter cells more efficiently than ZIF-8 (1.2K) and ZIF-8 (8K) NMOFs nanocomposites. For ZIF-8 (1.2K) and ZIF-8 (8K) NMOFs nanocomposites, the drug efficacy is overall comparable to free DOX in cell lines, depending on the concentrations of the drug. However, we expect that the ZIF-8−DOX can realize much better efficacy and smaller side effect in in vivo applications due to the enhanced permeability and retention (EPR) effect and the preferable release kinetics of nanomedicine.
3.3. In Vivo Study of ZIF-8 NMOFs Nanocomposites. Once we knew that ZIF-8 NMOFs nanocomposites have excellent properties and high cell killing efficiency, their application in in vivo anticancer therapy was next evaluated. In this study, ZIF-8 (8K) NMOFs nanocomposites were chosen as a drug delivery vector, because of its well-balanced drug loading capacity, pH sensitivity, and stability. In order to prolong the material's blood-circulation time, PEG (M w = 5000) was conjugated to PAAS (8K) molecule before nanocomposites fabrication (Scheme 2 and Figure S13 ). Then for drug loading, 1 mL of 1 mg/mL DOX was mixed with 1 mL of 1 mg/mL MOF-PEG nanocomposites for 24 h. During this process, almost all DOX was able to be loaded to MOF-PEG nanocomposites. This is the advantage of our ZIF-8 nanocomposites. The reason is PEG is conjugated to a PAAS template instead of ZIF-8 nanocrystal, and therefore it does not interfere with subsequent drug loading. After drug loading, the biodistribution of MOF-PEG DOX nanocomposites in mice was investigated by using a small animal in vivo fluorescence system to detect the fluorescence signal of DOX (Supporting Information Figure S15 ). It was found that DOX can be effectively delivered to the tumor site within 24 h, demonstrated by the very bright DOX fluorescence signal. At 48 h after injection, the fluorescence intensity in the tumor site further increased, while the fluorescence intensities in major organs including heart, liver, kidney, spleen, and lung starting to drop.
Since PEG modified MOF nanocomposites can effectively deliver DOX to tumor sites, it is expected that it can efficiently inhibit tumor growth. To verify this, a group of five mice was intravenously injected with MOF-PEG DOX (DOX dose at 2.5 mg/kg) and then the tumor volumes of the mice were monitored for 22 days. In addition, for comparison purposes, three other groups of mice were injected with PBS, free DOX (DOX), and MOF loaded with DOX but without PEG modification (MOF DOX). The results are shown in Figure 5a .
It is clear that the therapeutic efficacy of free DOX molecules and the DOX delivered by MOF nanocomposites without PEG surface modification is very low, indicated by the rapidly growing tumor during the observation period. In great comparison, MOF-PEG DOX constantly exhibits significantly improved therapeutic efficiency: more than 50% tumor reduction compared with the other three groups. There is a statistical difference between MOF-PEG DOX and other the three groups (p < 0.05). Moreover, there is minimal weight loss in the group treated with MOF-PEG DOX (Figure 5b) , indicating that the PEG modified MOF with MTX has great therapeutic efficacy with good biocompatibility. In addition, H&E staining of tumor slices was also evaluated. From the H&E staining, higher tumor cell damage is shown in the MOF-PEG DOX treated tumor, compared with MOF DOX, DOX, and PBS treated groups, which confirms that MOF-PEG DOX has better anticancer efficiency (Figure 5c ).
To investigate the mechanism of MOF-PEG DOX inhibition of tumor growth, immuno-histochemistry analysis of Caspase-3, KI-67, and CD31 as well as terminal deoxynucleotidyl transferased dUTP nick end labeling (TUNEL) was conducted ( Figure 6 ). Caspase-3, KI-67, and CD31 are the indicators for apoptosis, cell proliferation, and tumor angiogenesis, respectively. In Figure 6 , the mean optical densities (MODs) for Caspase-3 expression are 0.313 ± 0.001, 0.300 ± 0.006, 0.288 ± 0.001, and 0.277 ± 0.004 for MOF-PEG DOX, MOF DOX, DOX, and PBS treated groups, respectively. The higher expression of Caspase-3 in the MOF-PEG DOX treated group indicates that MOF-PEG DOX induces higher cell apoptosis than MOF DOX and DOX, thereby causing the death of tumor cells. For quantity analysis, the cell apoptosis was also evaluated by TUNEL, which showed 73.3 ± 4.04%, 34 ± 7%, 69.0 ± 2.6%, and 24.7 ± 2.5% apoptosis cells in MOF-PEG DOX, MOF DOX, DOX, and PBS treated groups, respectively. These confirm that MOF-PEG DOX can effectively kill tumor cells by inducing cell apoptosis.
In addition, we evaluated the level of KI-67, which is a key indicator for cell proliferation. Dramatically lowered expression of KI-67 was detected in MOF-PEG DOX treated tumor (MOD = 0.295 ± 0.013) compared with MOF DOX (MOD = 0.339 ± 0.013), DOX (MOD = 0.328 ± 0.016), and PBS (MOD = 0.345 ± 0.008) treated groups, indicating enhanced inhibition of the cancer cell proliferation. Finally, we analyzed CD31 protein, which is highly associated with tumor angiogenesis and tumor growth. In Figure 6 , lower CD31 expression is presented in the MOF-PEG DOX treated group, revealing that tumor growth was effectively inhibited. Microvascular density (MVD) was also counted (most vascularized area; in every slice five hot spots were selected), which is highly associated with tumor metastasis and prognosis. The average MVD results are 6.6 ± 1.1, 12 ± 1.6, 10.4 ± 2.7, and 16.6 ± 2 in MOF-PEG DOX, MOF DOX, DOX, and PBS treated groups, respectively. The MVD counting confirms the effectiveness of MOF-PEG DOX for tumor growth inhibition.
3.4. Biosafety Study of ZIF-8 NMOFs Nanocomposites. Biosafety is a major concern for clinical application of nanomedicine; therefore, we finally systematically investigated the toxicity of MOF-PEG DOX. First, histopathological examinations (H&E staining) were conducted to analyze major organs, including heart, liver, spleen, lung, and kidney ( Figure 7 ). From these H&E staining images, no obvious organ damage is shown in DOX and MOF-PEG DOX treated groups. Apparently, histopathological examinations demonstrate MOF-PEG DOX nanocomposites cause minimal toxicity to major organs. Because liver and kidney damage is a very common side effect of therapeutic drugs, to investigate he biosafety of MOF-PEG DOX, the liver and kidney function (Figure 8 ) of the treated mice were evaluated by measuring the blood serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), blood urea nitrogen (BUN), creatinine (CRE), and uric acid (UA). From the results, no obvious abnormality is found, indicating that MOF-PEG DOX nanocomposites have low toxicity toward liver and kidney, which is in line with our histopathological results. Since ZIF-8 NMOFs were intravenously injected, these drugs directly interacted with blood. Therefore, blood chemistry analysis was performed. There is also no significant abnormality of the complete blood counts data, including red blood cells (RBC), white blood cells (WBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and platelet count (PLT) ( Figure S16 ). Overall, all of these toxicity profiles suggest that MOF-PEG DOX has high biosafety for in vivo cancer therapy. 
CONCLUSION
In summary, we have developed a strategy of using PAAS as a soft template to prepare size controllable and surface modifiable ZIF-8-PAAS nanocomposites in the range of 30−200 nm which is suitable for drug delivery. The as-fabricated nanocomposites have ultrahigh drug loading capacity of up to 385 wt %. We also demonstrate that the nanocomposites fabricated from different PAAS nanospheres have different crystallinity, drug loading capacity, and release kinetics, and pH sensitivity. Also very importantly, these nanocomposites can be conveniently modified with functional molecules. As a test case, these nanocomposites were functionalized with PEG and employed as vectors to deliver DOX for cancer therapy with greatly enhanced efficacy in vitro and in vivo. Thus, this work provides a strategy to fabricate NMOFs nanocomposites with size tunability and flexible surface chemistry for various applications. 
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